Logo

Why treat mHSPC early with ERLEADA®?

Early treatment decisions are key to pushing back on disease progression[1]

Progression from mHSPC to mCRPC could take less than 1 year[1]a
Once patients progress to mCRPC, prognosis is poor[2]
2021 EAU guidelines: do not offer ADT alone to patients whose first presentation is M1 disease and who are willing to have and eligible for combination therapy[3]
Treating mHSPC patients early with ERLEADA® + ADT is associated with a lower frequency of AR aberrations relative to placebo + ADT[4][5]

The TITAN final analysis emphasises the benefit of early, potent, AR-signalling inhibition with ERLEADA® at the time of initial ADT for mHSPC and before progression to mCRPC.[1]

  • Patients with AR aberrations at the end of treatment had worse outcomes vs. patients without[4]
  • ERLEADA® + ADT was associated with decreased frequency of AR aberrations at the end of treatment vs. placebo + ADT[4][5]

Taken together, these findings suggest that early ERLEADA® + ADT provides long-term benefits vs. placebo + ADT without increased development of AR aberrations.[4]

aIn a Phase III study including patients with mHSPC on placebo + ADT.[1]

In mHSPC, early treatment decisions are key to pushing back on disease progression[1]

What if you could delay your patients’ progression to castration resistance and extend their lives?
Treat early with ERLEADA® + ADT to prolong survival & delay progression[1]
Treating early with ERLEADA® + ADT provides an additional treatment option for mHSPC patients[1]
Treating early with ERLEADA® + ADT helps maintain QoL[1]

Abbreviations

ADT, androgen deprivation therapy. AR, androgen receptor. EAU, European Association of Urology. M1, metastasised outside the pelvis. mCRPC, metastatic castration-resistant prostate cancer. mHSPC, metastatic hormone-sensitive prostate cancer. QoL, quality of life.

Referências

Chi KN, et al. J Clin Oncol 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
Luo J, et al. Oncology (Williston Park) 2016;30:336–344.
European Association of Urology. Prostate Cancer. Available at: https://uroweb.org/guideline/prostate-cancer/. Accessed: September 2021.
Chi KN, et al. Androgen receptor aberrations in patients with metastatic castration-sensitive prostate cancer treated with apalutamide plus androgen deprivation therapy in TITAN. European Society for Medical Oncology (ESMO) Congress. 27 September – 1 October 2019. Barcelona, Spain. Poster: 883P.
Chi KN, et al. Androgen receptor and non-androgen receptor aberrations associated with outcomes in metastatic castration-sensitive prostate cancer treated with apalutamide plus androgen deprivation therapy in TITAN. American Association for Cancer Research (AACR) 2020 Virtual Meeting II. 22–24 June 2020. Poster: 776.
CP-282954 - January 2022